Gluvecron MR

Gluvecron MR

gliclazide

Manufacturer:

Abio

Distributor:

Apex
Concise Prescribing Info
Contents
Gliclazide
Indications/Uses
Non-insulin-dependent diabetes (type 2), in association w/ dietary measures & w/ physical exercise, when these measures alone are not sufficient to obtain normal blood glucose levels.
Dosage/Direction for Use
Initially 30 mg daily, may be increased to 60, 90 or 120 mg daily in successive steps w/ at least 1 mth interval between each dose increment. Max daily dose: 120 mg. Switching: 1 tab gliclazide 80 mg is comparable to 1 tab gliclazide MR 30 mg.
Administration
Should be taken with food: Take at breakfast. Swallow whole.
Contraindications
Hypersensitivity to gliclazide, other sulphonylureas, sulphonamides; type 1 diabetes; diabetic pre-coma & coma, diabetic ketoacidosis; miconazole therapy. Severe renal or hepatic insufficiency. Lactation.
Special Precautions
Hypoglycaemia; malnutrition, irregular mealtimes, skipping meals, fasting or dietary changes, imbalance between physical exercise & carbohydrate intake, overdosage; thyroid disorders, hypopituitarism & adrenal insufficiency; G6PD-deficiency. Renal or severe hepatic insufficiency. Pregnancy.
Adverse Reactions
Hypoglycaemia, GI disturbances.
Drug Interactions
Increased hypoglycaemic effect w/ miconazole, phenylbutazone & alcohol. Potentiated blood glucose-lowering effect w/ other antidiabetic agents, β-blockers, fluconazole, ACE inhibitors, H2-antagonists, MAOIs, sulphonamides & NSAIDs. Increased blood glucose levels w/ danazol, chlorpromazine, glucocorticoids, ritodrine, salbutamol & terbutaline. Potentiation of anticoagulation during concurrent treatment.
MIMS Class
Antidiabetic Agents
ATC Classification
A10BB09 - gliclazide ; Belongs to the class of sulfonylureas. Used in the treatment of diabetes.
Presentation/Packing
Form
Gluvecron MR 30 mg tab
Packing/Price
10 × 10's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in